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Abstract Etiopathogenesis of migraine involves different
structures of the central nervous system: the trigeminal nerve
with nuclei located in the brain stem, vascular system, and the
cerebral cortex as well as diverse mechanisms and patholog-
ical processes. The multidirectional action of purines in differ-
ent cell types (blood vessels, neurons, and satellite glial cells)
and through different types of purinergic receptors contributes
to the etiopathogenesis of migraine pain. Adenosine triphos-
phate (ATP) and its derivatives are involved in initiation and
propagation of migrenogenic signals in several ways: they
participate in vasomotor mechanism, cortical spreading de-
pression, and in fast transmission or cross-excitation based
on the satellite glial cells in trigeminal ganglion. Contribution
of purinergic signaling in the conduction of pain is realized
through the activation of P1 and P2 receptors expressed wide-
ly in the central nervous system: on the neurons and glial cells
as well as on the smooth muscles and endothelium in the
vascular system. Therefore, the purinergic receptors can be
an excellent target for pharmacologists constructing new
antimigraine therapeutics. Moreover, the mechanisms facili-
tating ATP and adenosine degradation may prevent vasodila-
tation and thus avoid a secondary central sensitization during a
migraine attack. Thus, agonists and antagonists of P receptors
as well as ecto-enzymes metabolizing nucleotides/nucleosides
could gain the growing attention as therapeutic agents.
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Introduction
Migraine is defined as recurrent attacks of headache accom-
panied by autonomic symptoms, with the presence or absence
of aura (according to Headache Classification Committee of
the International Headache Society, 2013) [1].
Currently, it is known that the etiopathogenesis of migraine
involves different brain structures: the trigeminal nerve with
nuclei located in the brain stem, vascular system, the cerebral
cortex, and diverse mechanisms and pathological processes,
involving uncontrolled activation of the trigeminal nerve, va-
soconstriction and vasodilatation, and cortical spreading de-
pression [2]. These processes are mediated by pathologically
changed concentrations of extracellular signaling molecules
and neurotransmitters, and their action effects primarily in
the inflammation and pain. There is some evidence that con-
firms the involvement of purines in the above-mentioned pro-
cesses throughout the central nervous system [3].
Nucleotides participate in the pathophysiology of migraine
through influencing the vasomotor mechanism. Their effects
may be contradictory depending on the localization and type
of P receptors. Vasoconstriction of blood vessels in the brain
induces hypoxia, which stimulates the release of adenosine
triphosphate (ATP) from nerve endings to the vascular lumen.
ATP together with adenosine are the factors initiating relaxa-
tion of the blood vessels which results in an increased cerebral
blood flow and is linked with pain [4]. Presently, there are
reports that question the participation of vasomotor mecha-
nisms in the initiation of migraine, especially in terms of the
large brain arteries [2].
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The pivotal process in the initiation of migraine pain is the
activation of the trigemino-vascular system [5–8]. This pro-
cess causes the release of vasoactive molecules and activation
of their receptors on vascular smooth muscles [9]. It subse-
quently results in vascular relaxation, which is associated with
pain, an increase in the excitability of primary trigeminal neu-
rons and peripheral or central sensitization (allodynia) [10].
Themigrenogenic signals associated with the trigeminal nerve
are realized by painful stimuli mediated by fast transmitters
(like ATP) or based on the satellite glial cells that mediate the
conduction of painful stimuli (e.g., mediated by ecto-nucleo-
tides) deep into the nervous fiber [11].
More and more researchers and clinicians follow the
neural-vascular theory, combining initiation, amplification,
and propagation of migraine pain not only with vascular reac-
tion but also with the response of cortical neurons. During
cortical spreading depression, ATP is released into the brain
extracellular space and cerebrospinal fluid which results in the
activation and sensitization of afferent sensory fibers of the
trigeminal ganglion neurons and the transmission of nocicep-
tive signal [12].
It can be assumed that purinergic receptors can be a target
for pharmacologists constructing new antimigraine therapeu-
tics. Moreover, the mechanisms facilitating ATP and adeno-
sine degradation may prevent vasodilatation and thus avoid a
secondary central sensitization during the migraine attack.
This article is focused on the particular role of purinergic
system elements in the pathophysiological processes initiating
and amplifying the migraine pain. We also discuss the thera-
peutic perspectives of purinergic compounds as potential
drugs for the acute and preventive antimigraine treatment.
Purinergic signaling in the central nervous system
The nucleotides and adenosine are released into the extracellu-
lar matrix directly from neurons and astrocytes by exocytosis or
through a channel or pore. These molecules function as neuro-
transmitters and neuromodulators that regulate physiological
processes such as neurotransmission, proliferation, activation
of inflammation, or cell death [13]. Receptors for these com-
pounds are divided into P1 receptors (A1, A2A, A2B, A3)
activated by adenosine and P2 receptors activated by nucleo-
tides (ATP, ADP, UTP, UDP). Based on the fundamental dif-
ferences in their structure and mechanism of signal transduc-
tion, the P2 receptors are divided to metabotropic P2Y (1, 2, 4,
6, 11, 12, 13, 14) and ionotropic P2X receptors (1–7), which are
described as heteromultimers, e.g., P2X2/3, P2X1/5, and
P2X4/6 [14]. Both P1 and P2 receptors are present on most
cells throughout the central nervous system [15–17].
Extracellular nucleotide concentration and, thus, nucleotide-
mediated signals are controlled by ecto-nucleotidases: ecto-
nucleoside triphosphate diphosphohydrolases (ecto-NTPDases),
ecto-nucleotide pyrophosphohydrolases/phosphodiesterases
(ecto-NPPs), ecto-5′-nucleotidase (5′-NT), and ecto-nucleotide
kinases. In the central nervous system (CNS), these enzymes
are expressed on the cell surface of astrocytes, oligodendrocytes,
microglia, and endothelial cells. The high activity of NTPDase1
and NTPDase2 was observed on the cell membranes of the ce-
rebral cortex and hippocampus, while the activity of these en-
zymes in the cerebellum and the medulla oblongata is rather low
[18]. The final product of the degradation of extracellular ATP
and ADP is adenosine, further metabolized with the participation
of ecto-adenosine deaminase to inosine. In most areas of the
brain, there is a high activity of ecto-5′-nucleotidase and ecto-
adenosine deaminase.
It is known that in the CNS, adenine-derivative nucleotides
(ATP and ADP) and uracil derivatives (UTP, UDP, and UDP-
glucose) are associated with the sensory system and serve as
co-transmitters and/or neuromodulators. ATP, in addition to
participate in the fast synaptic signaling, affects also the sig-
naling mediated by other neurotransmitters. The correlation
between the concentration of ATP and catecholamine release
within the locus coeruleus and hippocampus was found [19].
There is also a correlation between the amount of ATP and
glutamate released in the hippocampal area [20, 21]. The ma-
jority of processes activated by ATP (e.g., secretion of gluta-
mate or propagation of inflammatory reactions) is inhibited by
adenosine (which inhibits glutamate release from astrocytes
and acts anti-inflammatory) formed during enzymatic degra-
dation of ATP. It indicates that under physiological conditions,
there is a balance between ATP-mediated activation and
quenching of these processes by adenosine [22].
In 1929, Drury and Szent-Gyorgyi demonstrated for the
first time the presence of purines in the blood vessels [23].
The role of purines in the physiology of the nervous system
was shown for the first time in 1972 [24], and in the 1980s,
Geoffrey Burnstock announced in the journal Lancet the hy-
pothesis concerning the participation of purinergic signaling
in the pathophysiology of migraine [25, 26]. Based on our
recent knowledge about the role of purinergic signaling in
brain, the aspect of purinergic drugs represents a promising
field for the investigation of novel purinergic migraine treat-
ment strategies.
The role of ATP and adenosine in the vasomotor
etiology of migraine
Thewidely offeredmigraine treatment is based on the vasomotor
theory, acts primarily on the vascular system, and leads to the
constriction of blood vessels within the brain. Triptans are at
present the most effective vasoactive drugs terminating a mi-
graine attack, by activation of serotonin receptors 5-HT1B on
arterial smooth muscles. They also inhibit the activity of periph-
eral trigeminal nerve endings by influencing the 5-HT1D or 5-
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HT1F receptors.Moreover, triptans inhibit neurons in the trigem-
inal sensory nuclear complex (TSNC) of the brain stem and
upper cervical spinal segments by an action on 5-HT1B/5-
HT1D/5-HT1F receptors. Unfortunately, many migraineurs do
not respond satisfactorily to triptans, and cardiovascular comor-
bidities (i.e., vasoconstriction in thoracic blood vessels) limit their
use in a significant number of patients [27, 28].
The earliest hypothesis for the initiation of migraine pain
was the vasomotor theory [29]. This theory assumes that mi-
graine attack consists of two stages. Initially, there is a vaso-
constriction (vasospasm), which results in tissue hypoxia but
is not accompanied by pain. It is known that local vasocon-
striction may be a consequence of activation of P2X receptors
present on smooth muscles through ATP released both as co-
transmitter with noradrenaline (NA) from perivascular sym-
pathetic nerves and from damaged endothelial cells (Fig. 1).
The intracellular stores (sympathetic noradrenaline stores) are
depleted of NA in the beginning of a migraine attack, which is
correlated with the increased release of co-transmitters and
other compounds such as dopamine, prostaglandins, ATP,
and adenosine [30]. Vasoconstriction is then followed by va-
sodilatation which results in reactive hyperemia associated
with pain perception [4]. Moreover, the synthesis of ATP
and its release from endothelial cells and platelets into blood
serum increase significantly during a migraine attack. The
released ATP activates the P2X and P2Y receptors (also acti-
vated by ADP, UTP, ADP) on the endothelial cells. Their
activation initiates the release of endothelium-derived relaxing
factor (EDRF) into the blood [3, 4]—Fig. 1. This Bpurinergic^
mechanism explains the dual involvement of purines in the
migraine headache initiation.
The cerebral vasculature has been crucial for various hy-
potheses concerning the pathophysiology of migraine.
Malmsjö and collaborators indicate that extracellular nucleo-
tides induce contractions of cerebral arteries primarily by ac-
tivation of P2Y6 receptors expressed on smooth muscle cells
[31]. A recent paper of Haanes and Edvinsson points out that
P2X1 and P2Y6 receptors are the strongest contractile recep-
tors in middle meningeal artery (MMA) and therefore regulate
the blood flow through the MMA. Adenosine acts as a
relaxing factor primarily via endothelial A2A receptors [32].
It has been shown that during a migraine attack, adenosine
concentration in the blood increases by about 47 % [33]. In-
volvement of adenosine in the etiology of migraine pain was
confirmed by intravenous administration of adenosine
resulting in migraine-like symptoms [34, 35]. Already in
1973, Paalzow and collaborators have found that methylxan-
thine, a nonselective antagonist of adenosine receptors, re-
duces the sensory nociceptive threshold in rats [36]. In pa-
tients treated with dipyridamole, an increase in migraine at-
tacks was noted, which may be associated with impaired in-
tracellular adenosine uptake from the extracellular space [37].
The observed effect of dipyridamole may, however, be linked
to both its inhibitory action on adenosine transporters as well
as the inhibition of phosphodiesterases (PDEs) and therefore
the increased concentrat ion of cycl ic guanosine
monophosphate (cGMP). As phosphodiesterase PDE5 is pres-
ent in platelets and smooth muscles of blood vessels, the in-
hibition of its activity and consequently an increase in cGMP
levels cause effects similar to adenosine: cerebral vasodilata-
tion and initiation of headache [38, 39]. However, the occur-
rence of headache may not depend so much on the
Fig. 1 The dual role of ATP
involved in vasomotor etiology of
migraine attack
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concentration of adenosine itself but on the increasing release
of neurotransmitters and other active compounds, such as cal-
citonin gene-related peptide (CGRP) [40, 41]. CGRP is re-
leased from nerve endings following depolarization. The com-
pound is one of the most potent vasodilatory factors through-
out the vascular system, especially in the microvasculature.
Activation of CGRP receptors on vascular smooth muscles
results in their relaxation, which is associated with pain during
a migraine attack [42]. Thus, headache may be related to ce-
rebral vasodilation, mainly within the middle cerebral artery,
which is responsible for blood supply for the dura mater. Ad-
ministration of CGRP causes initiation of headache, accom-
panied by dilation of both the middle meningeal artery and
middle cerebral artery [43]. It is worth noticing that activation
of G protein-coupled receptors sometimes triggers the phe-
nomenon known as transactivation, which results in synergic
or antagonist signaling. In the brain, the action of CGRP is
inhibited by A1 receptors and activated by A2A receptors.
The ability of A2A receptors to inhibit A1 receptors may also
contribute to further facilitation of CGRP action [44].
On the other hand, the adenosine-independent mechanism
was confirmed by Hegedus and collaborators, who demon-
strated a correlation between the decrease in cerebral blood
flow and blood levels of cAMP, but found no similar correla-
tion with the concentration of adenosine [45]. It is now be-
lieved that the vasodilation is not sufficient for the activation
of the headache, as vasodilation itself is observed, i.e., during
decrease in blood pressure.
ATP and adenosine in trigeminal nerve and satellite
glial cell pathophysiology
The trigeminal nerve is the fifth cranial nerve, which largely
consists of afferent sensory fibers, and is in the small percent-
age of the efferent motor fibers [5]. It comprises of three
branches: the ophthalmic nerve (V1), jaw nerve (V2), and
the mandibular nerve (V3). The key function of the sensory
part of the trigeminal nerve is the conduction of stimuli from
pain receptors (nociceptors), proprioceptors, mechanorecep-
tors, and temperature receptors.
Based on the recent knowledge, the key process in the
initiation of migraine pain is the activation of the trigemino-
vascular system. This process causes the release of vasoactive
molecules, such as calcitonin gene-related peptide, substance
P, and pro-inflammatory factors, and signaling molecules such
as ATP, serotonin, bradykinin, and prostaglandins. All of these
compounds affect both neurons and satellite glial cells (SGCs)
located in the trigeminal ganglion [9].
Adenosine is involved in the sensitization of trigeminal
neurons since it may inhibit this process [28, 46, 47]. There
are numerous reports on the potential role of A1 receptor
agonists in migraine and cluster headache. It has been
demonstrated that selective A1 receptor agonists (GR79236
and GR190178) inhibit the trigemino-vascular system, both
within the trigeminal nucleus, as well as by inhibiting the
release of CGRP in the vascular system, while not causing
the vasoconstriction [48, 49]. Unfortunately, the therapies
with A1 receptor agonists are limited by side effects, e.g.,
bradycardia and hypotension as the most severe of them.
The role of the other adenosine receptors (A2A, A2B, A3)
in the etiology of migraine is ambiguous. There are only few
reports suggesting that adenosine receptors can display anti-
nociceptive properties [50–52].
The role of ATP in the etiology of migraine was previously
associated only with the vascular theory of disease as de-
scribed above. Presently, the growing attention is paid to the
neuronal dysfunction and transmission of pain via ATP-
activated receptors within the trigeminal nerve. Contribution
of purinergic signaling in the conduction of pain in terms of P2
receptor activation byATP is relatively well known in the field
of the dorsal root and dorsal spinal cord and peripheral sensory
ganglia [15]. Moreover, the presence of P2X3, P2X2, and
P2X2/3 receptors, as well as P2Y1, P2Y2, P2Y4, P2Y6 re-
ceptors on neuronal cells of the trigeminal ganglion and dorsal
ganglia has been shown [14, 15, 53–55]. It was also described
that the P2Y1 and P2Y4 receptors present on trigeminal neu-
rons co-localize with the P2X3 receptor [56]. The satellite
glial cells expressed a similar set of P2Y receptors: P2Y1,
P2Y2, P2Y4, P2Y6 and P2Y12, and P2Y13 (together with
P2X2 and P2X2/3) [57, 58].
In vitro studies suggest that activation of P2X3 or P2X2/3
receptors present on afferent trigeminal nerve endings in the
dorsal horns of spinal cord causes an increase in the transmission
of pain impulses within the trigeminal nerve [59]. Central sensi-
tization of nociceptive neurons in brainstem may be affected by
intrathecal application of agonists and antagonists of the P2X
receptors [60]. It was also demonstrated that P2X3 receptor plays
a key role in trigeminal neuralgia [61]. The increased release of
calcitonin gene-derived protein (CGRP) is dependent on activa-
tion of the trigemino-vascular system and coexists with a sensi-
tization of P2X3 receptors [62]. This process plays an important
role in the further activation of the nerve cells and in the forma-
tion of peripheral and central sensitization.
The concept of P2Y receptors participation in the etiology
of migraine is relatively new and still unclear [3, 57, 63]. It is
believed that the possible effect of P2Y receptor activation is
both analgesic and algogenic [58]. P2Y1 receptor activation
may inhibit the P2X3 receptor activity in neurons of the dorsal
ganglia, suggesting the anti-algogenic role of ATP and ADP.
Intrathecal in vivo administration of UTP and UDP, other P2Y
receptor agonists, has been shown to have an analgesic effect,
probably due to the inhibition of cytokine release from glial
cells [64–66]. Some researchers also point out the participa-
tion of P2Y6 receptor located in the trigeminal ganglion neu-
rons in migraine etiology [64, 67].
310 Purinergic Signalling (2015) 11:307–316
Satellite glial cells (SGCs), participating in two-way com-
munication between neurons and glia, also enable the propa-
gation of inflammation and pain signals. It is believed that
excitation of neurons within the trigeminal ganglion may be
expanded not only along the main pathway of nerve impulses.
It has been found that nucleotides secreted by trigeminal gan-
glion neurons increase the calcium concentration inside the
satellite glial cells. This means that the satellite glial cells
using nucleotide signaling and calcium wave may transfer
information into the nervous system in the process called
Bcross-excitation^ [68]—Fig. 2.
Research of Weick and colleagues showed that, despite the
large representation of P2 receptors in SGC membranes, pain
stimuli are conducted only via P2Y1, P2Y2, and P2Y4 recep-
tor signaling [57]. Neural-glial communication within the tri-
geminal nerve is significantly weakened by carbenoxolone (a
potent blocker of gap junctions) and suramin, P2 receptor
antagonists with a broad spectrum of action [69]. That con-
firms the participation of extracellular nucleotides in the pro-
cess of neural-glial communication.
The hypothesis concerning participation of the SGCs in the
propagation of signals may explain the influence of peripheral
nervous system damage on the increase of the excitability of
many sensory neurons that can cause chronic pain [70]. Results
of Ceruti and colleagues, who used bradykinin (BK) as an
activator of sensory neurons, may expand this hypothesis with
the factors that cause sensitization of the sensory system and
link it to migraine headaches [8]. In the trigeminal ganglion
neuronal cultures, it was found that BK as an algogenic medi-
ator sensitizes the P2X3 receptors, which increases impulse
conduction to the trigeminal nuclei in the brainstem and the
conduction of painful stimuli in migraine. This process is pos-
sible by changing the expression and function of P2X receptors
initially through an increased trafficking of the receptor, follow-
ed by the increase in its synthesis [71]. It was also shown that
this receptor sensitivity may be affected by other mediators
such as CGRP, NGF, and BDNF [64, 72–74]. In the case of
P2Y receptors, bradykinin causes increased expression and in-
creased sensitization of these receptors. Further, it causes an
increase in the release of CGRP from trigeminal neurons, which
can also sensitize P2X3 receptor and enhance functions of P2Y
receptors on satellite glial cells [58, 71, 74, 75].
The increase in purinergic sensitivity of satellite glial cells
is accompanied by a significant increase in the release of pro-
and/or anti-inflammatory cytokines that can influence the in-
teraction between the cells in the trigeminal ganglion [76, 77].
The results of Takeda and colleagues suggest that activation of
the satellite glial cells modulates neuronal excitability within
trigeminal ganglion through the IL-1β released in the inflam-
matory process. At the same time, an increase in the IL-1β
receptor activity in the course of inflammation may contribute
to the occurrence of hyperalgesia [77]. The most extreme con-
sequence of hypersensitivity is allodynia, when a sensation of
pain is due to a stimulus that normally causes no pain. This
phenomenon is accompanied by the neurogenic inflammation
in the brain meninges. Evidence for the existence of central
sensitization (also referred to as skin allodynia in the area of
innervation by the trigeminal nerve) emerges from an analysis
of patients with migraine interviews. Some of them are
complaining about the sensitivity of the scalp to the small
tactile stimuli during daily activities such as washing the face,
shaving, and combing the hair. Otherwise, there is an
Fig. 2 Propagation of pain signal within the trigeminal ganglion (Bcross-
excitation^). Excitation potentials of neurons cause an increase in ATP
release outside the cell. ATP activates P2X receptors on the postsynaptic
cell membranes, as well as P2Y receptors on satellite glial cells (SGCs).
ATP released from neurons and satellite glial cells causes the spread of
Ca2+ waves in the neighboring cells, and the excitation spreads out
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activation of inflammatory processes, manifested in the pro-
duction and release of nucleotides and prostaglandins. The
easiest way to break the migraine attack at the stage of neuro-
genic inflammation in the meninges is using triptans or ergot-
amine to prevent the development of a secondary central sen-
sitization [78]. On the other hand, both blocking of the IL-1β
receptor, as well as modulation of nucleotide signaling, pre-
vent from pro-inflammatory interleukin secretion and may
become potential drugs to avoid hyperalgesia. It will be also
effective in the inhibition of another mechanism of neuronal
sensitization mediated by chronic trophic ATP influence and
neuronal plasticity [79, 80].
Cortical spreading depression
The aura is a set of specific symptoms and warning signs that
precede the migraine headache. This phenomenon occurs in
about 30% of patients with migraine [81–83]. The dominant
cause of the aura is the phenomenon of cortical spreading
depression (CSD), occurring 30–60 min before the migraine
headache attack [84, 85]. CSD consists of hypoperfusion
waves slowly spreading in the cerebral cortex, accompanied
by the wave of depolarization and the lack of neuronal activ-
ity, with subsequent activation of the trigemino-vascular sys-
tem [86, 87]. Awave of depolarization of neurons is preceded
by vasodilatation of cerebral vessels, both small and larger
ones [88].
It is presently well known that migraine headache is pre-
ceded by activation of nociceptive receptors in the meninges
and subsequent activation of the sensory fibers of trigeminal
neurons that innervate the blood vessels within the meninges
[89]. Recently, Zhang and colleagues demonstrated for the
first time that CSD activates not only the primary neurons of
the trigeminal ganglion but also the secondary neurons located
in the upper segments (C1–C2) of the spinal cord [90]. Such
molecules as ATP, nitric oxide, prostaglandins, and potassium
ions (K+) are released into the cerebrospinal fluid during cor-
tical spreading depression [91, 92]. The increase in the con-
centration of these molecules results in the activation and sen-
sitization of afferent sensory fibers of the trigeminal ganglion
neurons and the transmission of nociceptive stimuli from me-
ninges to secondary neurons of the trigeminal nerve (trigem-
inal sensory nuclear complex, TSNC) located in the brain
stem and upper cervical spinal segments. Already in the peri-
od of increased activity of the cerebral cortex that is directly
followed by CSD, there is a significant increase in the con-
centration of ATP in the intercellular space. ATP is responsible
for the activation and amplification of nociceptive signal
transmission and inflammation, and it consequently leads to
the activation and sensitization of afferent sensory fibers [91,
92]. The nociceptive and proinflammatory effect of ATP is
triggered by the activation of P2X and P2Y receptors, present
on the primary afferent fibers, primarily on the nociceptive
fibers C [3, 15, 93–95].
Most of the nociceptive trigeminal neurons, that innervate
the dura, express P2X3 receptors and are capable of releasing
calcitonin gene-derived protein (CGRP) [14, 66]. P2X3 recep-
tor activation facilitates the release of CGRP within the dura
mater and promotes the initiation of inflammatory processes,
as well as the further release of CGRP in the trigeminal nuclei
of the brainstem and, consequently, causes sensitization of
secondary neurons involved in the transmission of painful
stimuli [96]. Moreover, CGRP causes sensitization of noci-
ceptive receptor P2X3 present in the trigeminal ganglion
[66]. Studies of Masterson and collaborators showed that di-
hydroergotamine (DHE), through the activation of α(2)-
adrenoreceptors, blocks ATP-induced sensitization of trigem-
inal neurons, inhibits the release of CGRP, and reduces the
expression of membrane receptor P2X3 [96].
Therapeutic perspectives
Despite the complexity of migraine pathophysiology, substan-
tial advances have been achieved over the past 20 years in its
understanding and development of pharmacological treat-
ment. Triptans, agents with the vasoconstrictor activity, are
currently the most effective drugs in the interruption of a mi-
graine attack. However, there is a significant need for novel
therapeutic drugs for the acute and preventive treatment of
migraine [97]. Based on the experimental evidence presented,
it has become increasingly apparent that the purinergic system
significantly contributes to nociceptive signaling. The multi-
directional action of purines in different cell types (blood ves-
sels, neurons, and satellite glial cells) and through different
types of purinergic receptors contributes to the initiation and
amplification of migraine pain. Therefore, the purinergic re-
ceptors can be an excellent target for pharmacologists con-
structing new antimigraine therapeutics [98]. Adenosine has
been reported to trigger migraine attack while dipyridamole,
an adenosine uptake inhibitor, can increase migraine attack
frequency. Therefore, A1 receptor stimulation has been al-
ready proposed for migraine treatment [99]. Unfortunately, a
significant limitation of use of A1 receptor agonists is their
side effects outside the central nervous system as described
above. Results of recent studies indicate that acute, long-
lasting sensitization of trigeminal nociceptive neurons occurs
via enhanced expression of ATP-gated P2X3 receptors [73].
The P2X3 receptor is the only ligand-gated channel known to
be expressed exclusively by a subset of trigeminal and spinal
sensory neurons and may be a promising candidate for
antimigraine drug development [100]. The problem of devel-
oping migraine treatment based on purinergic signaling is due
to insufficient knowledge about the effects of activation of
P2X receptors and P2Y present in the trigeminal ganglion
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neurons and satellite glial cells by adenine nucleotides (ATP
and ADP) and uracil derivatives (UTP, UDP, and UDP glu-
cose). Because it is believed that the effect of these nucleotides
is algogenic, it is possible to achieve analgesic effect with
intravenous or intrathecal application of P2X and P2Y recep-
tors antagonists. The studies on highly specific, non-
nucleotide P2X3 and P2X2/3 receptor antagonists, such as
A-317491 and AF-219, were already published [101–103].
AF-219 was confirmed as an excellent medicinal candidate
to establish the role of P2X3 receptors in chronic pain and
related conditions. The compoundwas particularly efficacious
in rodent models of hyperalgesia (neuropathic and inflamma-
tory) or visceral hypersensitivity [103]. The favorable phar-
macodynamic and pharmacokinetic properties as well as
in vivo activity of AF-219 result in its further exploration in
clinical trials.
As seen from clinical trials, the current therapeutic strate-
gies for CNS disorders, including migraine, focus rather on
the use of P1 and P2 receptor antagonists. It is important to
note that most of the analyzed receptor antagonists partially
inhibit nucleotidase activity, so they indirectly participate in
maintaining high ATP concentration. Ecto-NTPDase1 knock-
out augmented purinergic vasorelaxation in vitro and the hy-
potensive effects of purines in vivo [104]. We postulate that
upregulation of ATP metabolism in the local environment of
cells through ecto-NTPDase activation or delivery may pro-
vide the best therapeutic solution [105]. The mechanisms fa-
cilitating ATP and adenosine degradation may prevent vaso-
dilatation and thus avoid a secondary central sensitization dur-
ing a migraine attack. Therefore, ecto-enzymes metabolizing
nucleotides/nucleosides could gain growing attention as ther-
apeutic agents. The complexity of the purinergic signaling
system poses several limitations, especially in the translation
to the clinic. Limited evidence is available on the spatiotem-
poral characterization of the purinergic effects in the trigemi-
nal vascular system in vivo. These issues are complicated by
the lack of an appropriate animalmodel representative of com-
plex migraine pathology. However, we should not forget that,
in the future, drugs for migraine may be ecto-enzymes them-
selves or compounds that modulate their activity.
Summary
No hypothesis has yet been proved capable of explaining all
the features of migraine headache. However, the purinergic
signaling system gains the growing interest in terms of its
involvement in migraine etiology as well as in its potential
therapeutic importance. ATP and its derivatives are involved
in initiation and propagation of migrenogenic signals in sev-
eral ways: they participate in vasomotor mechanism, cortical
spreading depression, and in fast transmission or cross-
excitation based on the satellite glial cells in trigeminal
ganglion.
ATP is involved in vasoconstriction and vasodilatation, and
the latter is accompanied by the occurrence of pain. The
vasoconstrictory effect of ATP originates from the local acti-
vation of the P2X receptors present on smooth muscles. The
coaction of ATP and other compounds such as noradrenaline,
dopamine, and prostaglandins is responsible for effective va-
soconstriction. The ATP involvement in the process of the
vasodilatation effects in activation of endothelial P2X and
P2Y receptors, followed by the release of the endothelium-
derived relaxing factor (EDRF) into blood. It is also believed
that the increase in the concentration of adenosine in the ex-
tracellular space, including the blood, may trigger vasodilata-
tion and thereby cause headache.
During cortical spreading depression, there is a significant
increase in the concentration of ATP in the intercellular space
followed by its release to the cerebrospinal fluid. The elevated
concentration of ATP and other active molecules results in the
activation and sensitization of afferent sensory fibers of the
trigeminal ganglion neurons and transmission of nociceptive
information from the meninges to the secondary trigeminal
neurons via P2X3 receptor.
The presence of P2X and P2Y purinoreceptors on trigem-
inal ganglion neurons and glial satellite cells, as well as the
discovery of their participation in the conduction of nocicep-
tive stimuli, confirms the role of nucleotides in the
etiopathogenesis of migraine. The presence of the A1 recep-
tors on trigeminal neurons suggests that adenosine is also
involved in the sensitization of these neurons.
The multidirectional action of purines in different cell types
(blood vessels, neurons, and satellite glial cells) and through
different types of purinergic receptors contributes to the initi-
ation and amplification of migraine pain. Therefore, the
purinergic receptors can be an excellent target for pharmacol-
ogists constructing new antimigraine therapeutics. It can be
also assumed that the mechanisms facilitating ATP and aden-
osine degradation may prevent vasodilatation and thus avoid a
secondary central sensitization during the migraine attack.
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